- Home
- BMEA vs MGX Comparison
BMEA vs MGX Comparison
Compare BMEA & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- MGX
- Stock Information
- Founded
- BMEA 2017
- MGX 2018
- Country
- BMEA United States
- MGX United States
- Employees
- BMEA N/A
- MGX N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- MGX
- Sector
- BMEA Health Care
- MGX
- Exchange
- BMEA Nasdaq
- MGX NYSE
- Market Cap
- BMEA 275.6M
- MGX 74.5M
- IPO Year
- BMEA 2021
- MGX 2024
- Fundamental
- Price
- BMEA $11.42
- MGX $1.99
- Analyst Decision
- BMEA Buy
- MGX Strong Buy
- Analyst Count
- BMEA 13
- MGX 7
- Target Price
- BMEA $36.33
- MGX $15.50
- AVG Volume (30 Days)
- BMEA 1.0M
- MGX 371.8K
- Earning Date
- BMEA 10-28-2024
- MGX 11-12-2024
- Dividend Yield
- BMEA N/A
- MGX N/A
- EPS Growth
- BMEA N/A
- MGX N/A
- EPS
- BMEA N/A
- MGX N/A
- Revenue
- BMEA N/A
- MGX $55,929,000.00
- Revenue This Year
- BMEA N/A
- MGX $0.39
- Revenue Next Year
- BMEA N/A
- MGX N/A
- P/E Ratio
- BMEA N/A
- MGX N/A
- Revenue Growth
- BMEA N/A
- MGX 83.36
- 52 Week Low
- BMEA $3.61
- MGX $1.85
- 52 Week High
- BMEA $22.74
- MGX $12.74
- Technical
- Relative Strength Index (RSI)
- BMEA 68.67
- MGX 32.65
- Support Level
- BMEA $10.35
- MGX $1.97
- Resistance Level
- BMEA $11.83
- MGX $2.13
- Average True Range (ATR)
- BMEA 0.93
- MGX 0.13
- MACD
- BMEA 0.02
- MGX 0.04
- Stochastic Oscillator
- BMEA 58.54
- MGX 23.33
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).